Vivek Subbiah, MD, Karisa Schreck, MD, PhD, and Rimas Lukas, MD, offer insights into integrating tumor agnostic therapies for actionable genetic alterations across solid tumors https://lnkd.in/egHZDDf7
About us
OncLive is the official website for the Intellisphere, LLC Oncology Specialty Group, which publishes OncologyLive, Urologists in Cancer Care, Oncology Nursing News, and Oncology Fellows. The mission of OncLive is to arm oncology professionals with the resources and information they need to provide the best patient care. We cover every angle of oncology practice, from new technology to treatment advances to important regulatory decisions. OncLive allows the Oncology Specialty Group to add features and tools not possible with print, such as social media feeds, breaking news, and live coverage from major oncology meetings.
- Website
-
http://onclive.com
External link for OncLive
- Industry
- Book and Periodical Publishing
- Company size
- 51-200 employees
- Headquarters
- Cranbury, NJ
- Type
- Privately Held
Locations
-
Primary
2 Clarke Dr
Cranbury, NJ 08512, US
Employees at OncLive
-
Chelsea DeLisa
Senior National Account Manager at OncLive, an MJH Life Sciences Brand
-
Chandler Park, M.D., F.A.C.P.
Award Winning Oncologist| 3x NEJM Published Author| ASCO Faculty|Advisory Dean/Clinical Professor UofL Medical School|Kentucky Leader ASCO ASH NCCN…
-
Morgan Burum
Director of Sales
-
Gabrielle Gelchion
National Account Manager, Onclive Events™
Updates
-
IDE937 produced responses in patients with advanced urothelial cancer or non–small cell lung cancer harboring MTAP deletions. #oncology #NSCLC https://lnkd.in/e9qdQhFt
IDE937 Generates Responses in NSCLC and Urothelial Cancer Harboring MTAP Deletions
onclive.com
-
Moleculin Biotech completed an end-of-phase 2 meeting with the FDA regarding the investigation of annamycin plus cytarabine in acute myeloid leukemia. #oncology #AML https://lnkd.in/eJ3Ri7TH
FDA Completes End-of-Phase 2 Meeting for Annamycin Plus Cytarabine in AML
onclive.com
-
That's a wrap on #KCRS24 Thank you to all of our interviewees and stay tuned to onclive.com for our continued coverage of the meeting.
-
-
-
-
-
+1
-
-
Join MedNews Week on July 13th for a deep dive into Carving Out A Career in Medical Education with Sam Brondfield, MD, MA #MedicalSpotlight Register now: https://ow.ly/HjWh50SxkcM
-
-
Karl Semaan, MD, MSc, of Dana-Farber Cancer Institute, discusses the utility of liquid biopsy epigenomic profiling for the detection of sarcomatoid renal cell carcinoma. #KCRS24 #kcsm https://lnkd.in/eWCc4hit
Dr Semaan on Liquid Biopsy Epigenomic Profiling for the Detection of Sarcomatoid RCC
onclive.com
-
Bradley McGregor, MD, of Dana-Farber Cancer Institute and Harvard Medical School, discusses findings from a phase 1b study evaluating abemaciclib in patients with clear cell renal cell carcinoma. https://lnkd.in/ePXyn2dM
Dr McGregor on the Data for Abemaciclib in Advanced ccRCC
onclive.com
-
Laurence Albiges, MD, PhD, discusses research evaluating treatments for subtypes of non–clear cell renal cell carcinoma. #KCRS24 #RCC KidneyCAN https://lnkd.in/eSGhyaua
Ongoing Research Aims to Identify Treatment Approaches for Non–Clear Cell RCC Subtypes
onclive.com
-
Myelodysplastic Neoplasms (MDS) and Acute Myeloid Leukemia (AML) are two related but distinct disease entities requiring differential treatment approaches. Gain insight into the biological, morphological, and clinical differences between the two diseases, and why patient-centric, tailored treatment approaches are important for patients with either MDS or AML. Watch this video: https://bit.ly/4eDzQ0u
-
-
In this episode of OncLive On Air, Paul K. Paik, MD, of Memorial Sloan Kettering Cancer Center, discusses the VISION trial of frontline tepotinib in patients with NSCLC harboring MET exon 14 skipping mutations! https://lnkd.in/eHCbF3_m
-